Abstract
Imatinib mesylate is a selective tyrosine kinase inhibitor that inhibits the tyrosine kinase of bcr-abl, PDGF receptor, SCF, c-kit and other receptors at the cellular level. It Inhibits cell proliferation and induces apoptosis. Imatinib is the first-line drug for the treatment of gastrointestinal stromal tumor. The most common adverse reactions of Imatinib are edema, skin rash, fatigue, nausea and neutropenia, But the induction about hyperplasia of keloid in patients has not been reported. This case suggests that imatinib may lead to hyperplasia of skin keloid, possibly by influencing the immune system of patients with gastrointestinal stromal tumor. Key words: Gastrointestinal stromal tumor; Imatinib; Keloid
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
